Printer Friendly

Cetirizine a safe antihistamine in long QT syndrome.

SAN FRANCISCO -- Cetirizine appears to be the antihistamine of choice for patients with long QT syndrome because of the drug's lack of effect on ventricular repolarization, Dr. Anna-Mari Hekkala said at the annual meeting of the Heart Rhythm Society.

Prolongation of the QT interval has been a problem with some other antihistamines. Two nonsedating ones--terfenadine and astemizole--have been removed from the U.S. market for this reason. Any prolongation of the QT interval would be of particular concern in patients with long QT syndrome because it would exacerbate their increased risk of sudden cardiac death, said Dr. Hekkala of the University of Helsinki (Finland).

She reported on 30 asymptomatic patients with one of the two most common forms of congenital long QT syndrome. Half had the HERG mutation; the rest had the KCNQ1 mutation. They took 10 mg/day of cetirizine for 4 days and 10 mg of placebo daily for another 4 days, as did 15 healthy control subjects. After each dosing, their ECGs were studied at rest and during maximal exercise stress testing.

Cetirizine had no significant effect on QT interval at rest, during exercise, or during recovery. Nor did 10 mg of cetirizine affect resting or maximal heart rate, blood pressure, or achieved workload. In fact, in patients with either form of long QT syndrome, cetirizine was tied to significant shortening of the T-wave end, resulting in a salutary mild reduction in transmural dispersion of repolarization.
COPYRIGHT 2004 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Author:Jancin, Bruce
Publication:Internal Medicine News
Article Type:Brief Article
Geographic Code:1USA
Date:Oct 1, 2004
Words:239
Previous Article:Dronedarone prevented atrial fibrillation recurrences without toxicity in two trials.
Next Article:Genetic differences affect responses to medications.
Topics:


Related Articles
Eurand Technology Used in New UCB Specialty
Occasional Antihistamines Safe in Pregnancy.
Zafirlukast plus antihistamine in IgE-receptor-positive hives. (Clinical Rounds: For resistant cases).
Chronic urticaria.
Pediatric allergic rhinitis: factors affecting treatment choice.
Genaissance Obtains License to Vanderbilt Patent Linking Genetics to Key Drug Safety Issue; - Method helps identify experimental drugs that may...
Eurand's AdvaTab Cetirizine Successfully Meets Major Development Milestone.
Efficacy and central nervous system impairment of newer-generation prescription antihistamines in seasonal allergic rhinitis.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters